S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

4D Molecular Therapeutics Stock Forecast, Price & News

-0.33 (-1.43%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
179,990 shs
Average Volume
205,956 shs
Market Capitalization
$732.15 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive FDMT News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

4D Molecular Therapeutics logo

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.


4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $21.42
November 30, 2021 |  americanbankingnews.com
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $24.15
November 19, 2021 |  americanbankingnews.com
4D Molecular Therapeutics Inc.
October 15, 2021 |  barrons.com
See More Headlines

Industry, Sector and Symbol

Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$13.61 million


Pretax Margin




Free Float
Market Cap
$732.15 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.23 out of 5 stars

Medical Sector

356th out of 1,390 stocks

Analyst Opinion: 3.3Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

4D Molecular Therapeutics (NASDAQ:FDMT) Frequently Asked Questions

Is 4D Molecular Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 4D Molecular Therapeutics stock.
View analyst ratings for 4D Molecular Therapeutics
or view top-rated stocks.

Are investors shorting 4D Molecular Therapeutics?

4D Molecular Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,180,000 shares, a drop of 26.3% from the October 31st total of 1,600,000 shares. Based on an average daily trading volume, of 255,400 shares, the short-interest ratio is currently 4.6 days. Approximately 4.6% of the shares of the stock are sold short.
View 4D Molecular Therapeutics' Short Interest

When is 4D Molecular Therapeutics' next earnings date?

4D Molecular Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for 4D Molecular Therapeutics

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.01. The firm had revenue of $1.37 million for the quarter.
View 4D Molecular Therapeutics' earnings history

What price target have analysts set for FDMT?

3 brokerages have issued 1-year target prices for 4D Molecular Therapeutics' stock. Their forecasts range from $44.00 to $47.00. On average, they expect 4D Molecular Therapeutics' stock price to reach $45.50 in the next twelve months. This suggests a possible upside of 99.7% from the stock's current price.
View analysts' price targets for 4D Molecular Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are 4D Molecular Therapeutics' key executives?

4D Molecular Therapeutics' management team includes the following people:
  • Dr. John F. Milligan, Exec. Chairman (Age 60, Pay $55.84k)
  • Dr. David H. Kirn, Co-Founder, CEO, Pres & Director (Age 58, Pay $701.53k)
  • Mr. August J. Moretti, Chief Financial Officer (Age 70, Pay $632.76k)
  • Dr. David E. Schaffer Ph.D., Co-Founder, Chief Scientific Advisor & Independent Director (Age 51, Pay $108.38k)
  • Dr. Robert S. Fishman, Chief Medical Officer & Therapeutic Area Head of Pulmonology (Age 59, Pay $184.62k)
  • Ms. Theresa Janke, Co-Founder & Chief Strategy Officer (Age 47)
  • Dr. Fred Kamal Ph.D., COO & CTO (Age 59)
  • Dr. Peter Francis B.Sc., M.D., Ph.D., Chief Scientific Officer & Head of Ophthalmology Therapeutic Area (Age 53)
  • Jessica Wilan, Sr. VP of HR
  • Dr. Raphael Schiffmann M.D., Sr. VP & Therapeutic Area Head of Cardiology

When did 4D Molecular Therapeutics IPO?

(FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

What is 4D Molecular Therapeutics' stock symbol?

4D Molecular Therapeutics trades on the NASDAQ under the ticker symbol "FDMT."

Who are 4D Molecular Therapeutics' major shareholders?

4D Molecular Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (4.73%), BlackRock Inc. (5.33%), ArrowMark Colorado Holdings LLC (3.12%), Morgan Stanley (1.37%), Centiva Capital LP (1.33%) and Centiva Capital LP (1.12%).
View institutional ownership trends for 4D Molecular Therapeutics

Which institutional investors are selling 4D Molecular Therapeutics stock?

FDMT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, ArrowMark Colorado Holdings LLC, Janus Henderson Group PLC, and Citadel Advisors LLC.
View insider buying and selling activity for 4D Molecular Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying 4D Molecular Therapeutics stock?

FDMT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Centiva Capital LP, Centiva Capital LP, Geode Capital Management LLC, Russell Investments Group Ltd., Bank of New York Mellon Corp, The Manufacturers Life Insurance Company , and Goldman Sachs Group Inc..
View insider buying and selling activity for 4D Molecular Therapeutics
or or view top insider-buying stocks.

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 4D Molecular Therapeutics' stock price today?

One share of FDMT stock can currently be purchased for approximately $22.78.

How much money does 4D Molecular Therapeutics make?

4D Molecular Therapeutics has a market capitalization of $732.15 million and generates $13.61 million in revenue each year.

How many employees does 4D Molecular Therapeutics have?

4D Molecular Therapeutics employs 83 workers across the globe.

What is 4D Molecular Therapeutics' official website?

The official website for 4D Molecular Therapeutics is www.4dmoleculartherapeutics.com.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.